Rh-Endostatin Combined With CCRT(50 Gy) Followed by Durvalumab Maintenance for the Treatment of Specific Phase III NSCLC

Inclusion Criteria:

* Age at 18-75 years.
* Documented evidence of NSCLC (locally advanced, unresectable, Stage III)
* Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST)
* Eastern Cooperative Oncology Group performance status score (ECOG PS) of 0 to 1.
* Estimated life expectancy of more than 12 weeks.

Exclusion Criteria:

* Prior exposure to any anti-PD-1 or anti-PD-L1 antibody.
* Active or prior autoimmune disease or history of immunodeficiency.
* Evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including hepatitis B, C and HIV.
* Evidence of uncontrolled illness such as symptomatic congestive heart failure, uncontrolled hypertension or unstable angina pectoris.
* Any unresolved toxicity CTCAE \>Grade 2 from the prior chemoradiation therapy.
* Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).